Clinical Study

Epidemiology, Prognosis, and Evolution of Management of Septic Shock in a French Intensive Care Unit: A Five Years Survey

Nicolas Boussekey, Juliette Cantrel, Lise Dorchin Debrabant, Joachim Langlois, Patrick Devos, Agnes Meybeck, Arnaud Chiche, Hugues Georges, and Olivier Leroy

Intensive Care and Infectious Disease Unit, Tourcoing Hospital, University of Lille, 135, rue du Président Coty, BP 619, 59208 Tourcoing, France

Correspondence should be addressed to Nicolas Boussekey, nboussekey@ch-tourcoing.fr

Received 18 November 2009; Accepted 29 April 2010

Academic Editor: Jordi Rello

Copyright © 2010 Nicolas Boussekey et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To evaluate the epidemiology, prognosis, and management of septic shock patients hospitalized in our intensive care unit (ICU). Material and Methods. Five-year monocenter observational study including 320 patients. Results. ICU mortality was 54.4%. Independent mortality risk factors were mechanical ventilation (OR = 4.97), Simplify Acute Physiology Score (SAPS) II > 60 (OR = 4.28), chronic alcoholism (OR = 3.38), age >65 years (OR = 2.65), prothrombin ratio <40% (OR = 2.37), and PaO₂/FiO₂ ratio <150 (OR = 1.91). These six mortality risk factors recovered allow screening immediately septic shock patients with a high mortality risk. Morbidity improved with time (diminution of septic shock complications, increase of the number of days alive free from mechanical ventilation and vasopressors on day 28), concomitant to an evolution of the management (earlier institution of all replacement and medical therapies and more initial volume expansion). There was no difference in mortality. Conclusion. Our study confirms a high mortality rate in septic shock patients despite a new approach of treatment.

1. Introduction

A better pathophysiologic knowledge and the apparition of international recommendations allowed an improvement of septic shock’s prognosis, but mortality still remains above 50% [1, 2]. Numerous factors are associated to mortality in septic shock. Early recognition of these factors can help to identify the most critical situations and to provoke a more aggressive resuscitation. We realized an observational study including all the patients suffering from septic shock and hospitalized in our intensive care unit (ICU) from 2003 to 2007. Beyond an epidemiologic analysis, we wanted to identify mortality risk factors and evolution of septic shock management in our ICU.

2. Material and Methods

2.1. Inclusion Criteria and Study Aims. We included all the patients suffering from septic shock and hospitalized in the ICU of Tourcoing hospital, France, between January 2003 and January 2008. Our study had 3 aims: an epidemiologic record, the identification of independent mortality risk factors, and the evaluation of management and prognosis comparing 2 periods, before and after the publication of the Surviving Sepsis Campaign (SSC) international guidelines in December 2004 [3].

2.2. Data Collection and Definitions

2.2.1. On Admission. For all patients, the following characteristics were prospectively collected on ICU admission: age, gender, underlying clinical conditions, severity of illness, and vital sign abnormalities. Severity of illness was assessed by the Simplified Acute Physiology Score (SAPS) II [4] and the Sepsis-related Organ Failure Assessment (SOFA) score [5]. We estimated an organ dysfunction if the score for this organ was superior to 3. Septic shock was defined as a sustained (≥1h) decrease in the systolic blood pressure of at least 40 mmHg from baseline or a resultant systolic blood pressure <90 mmHg after adequate fluid replacement.
and in the absence of any antihypertensive drug [6]. We recorded the community or hospital-acquired origin of the infection, bacteriological data and if the patient presented coinfection (more than one pathologic bacteria recovered). We also noted the delay from the hospital admission, from the onset of the sepsis and the septic shock, to the admission in the ICU. We recorded all the bacteriological samples as well as the initial antibiotic therapy. Antibiotic therapy was defined as adapted (if it followed recommendations), and adequate (if it compartment at least one antibiotic active in vitro on the causal bacteria). Delay from the onset of the sepsis to the start of the antibiotic treatment was also noted.

Volume expansion with hydroxyethylstarches (HES), cristalloids, 4% albumin and packed red blood cells was quantified at 6 and 24 hours after the onset of the sepsis as well as vasopressor use. We also recorded the use of activated protein C, hydrocortisone, intensive insulin therapy, type and amount of nutrition, need for mechanical ventilation or renal replacement therapy (RRT). We also noted the time from the beginning of vasopressors and the prescription of hydrocortisone, nutrition, ventilation, and RRT.

2.2.2. Evolution. We recorded if the patients presented a recurrence of shock (need for vasopressor after 8 hours weaning). During the ICU stay, occurrence of complications was recorded. We distinguished infection-related complications (acute respiratory distress syndrome (ARDS), acute renal failure, disseminated intravascular coagulation, and acute hepatic failure) and hospital-acquired infections. Finally, we recorded the number of days alive free from mechanical ventilation, vasopressors, and RRT on day 28. Mortality was evaluated on day 28 and at ICU discharge.

2.3. Statistical Analysis. To determine the factors associated with mortality, we realized a logistic regression analysis. First, we performed a monovariate analysis, and then pooled the significant parameters ($P < .2$) in a multivariate analysis with the estimate of the Odds Ratio (OR). For multivariate analysis, an area under the curve was used to determine the cut-off of continuous variables. Comparisons between groups were performed using Chi-square test or Fisher’s exact test for categorical parameters. Continuous variables were analysed using Wilcoxon’s test. Differences between groups were considered to be significant for variables yielding a P value < .05. All analyses were performed using the SAS Software, V8.2.

3. Results

3.1. Baseline Characteristics on Admission. Between January 2003 and January 2008, 320 patients were hospitalized in our ICU for septic shock. Sixty three percent of the population was male, mean age was 65 ± 15.3 years, SAPS II and SOFA score were 62.3 ± 20.1 and 11.3 ± 3.2, respectively. The major comorbidity was chronic alcoholism (26.8%), followed by chronic obstructive pulmonary disease (COPD (25.2%)), diabetes mellitus (21.8%), and chronic cardiac failure (18%). Associated organ failures were respiratory (83.6%), neurologic (35.7%), renal (26.3%), coagulation (15.2%), and hepatic (3.5%). Mean times from the hospital admission, the onset of the sepsis and the septic shock to ICU admission were 3.8 ± 7.5 days, 16.7 ± 28.8 hours, and 2.4 ± 4.8 hours, respectively.

3.2. Bacteriology and Antibiotic Therapy. The sepsis was community-acquired in 64% of the patients. Infection site was predominantly respiratory (48.4%), followed by intraabdominal (20%) and urinary (8.7%). The infection was bacteriologically documented in 59% of the patients, with 33% of positive blood cultures. 20.4% of the patients presented coinfections. Causative pathogens were Gram-positive cocci in 45.3% of the positive cultures, mostly represented by Streptococcus pneumoniae (17.4%) and Staphylococcus aureus methicillin-sensitive (11.6%), and methicillin-resistant (4.2%). Gram-negative bacilli were found in 43.2%: Escherichia coli (15.8%), Klebsiella (5.3%), and Pseudomonas aeruginosa ticarcillin-sensitive (4.7%) and ticarcillin-resistant (3.7%). Anaerobes bacteria represented 3.7% and Candida 2.6% of the cases. Mean time from the onset of the sepsis to the introduction of antibiotics was 9.8 ± 18.7 hours. It was adapted in 97% and adequate in 88% of the patients.

3.3. Management. Mean plasma volume expansion during the 24 hours following the sepsis was 1160 ± 793 mL for HES and 2194 ± 1720 mL for cristalloids. The most used vasopressor agent was norepinephrine in 74%, followed by dopamine (42%), dobutamine (26%), and epinephrine (16%). Only 7% of the patients received activated protein C. Hydrocortisone was prescribed in 84% of the population, 7.9 ± 12 hours after the onset of shock. Mechanical ventilation was needed in 88%; noninvasive ventilation was performed in 13% of the patients. Thirty one percent of the patients needed RRT.

3.4. Prognosis on Day 28. Recurrence of shock was noted in 24% of the population, complications of septic shock in 28.2% and hospital-acquired infections in 25.7% with 32% of multiresistant bacteria. ICU mortality was 54.4%, day 28 mortality 51.2%. Time alive free from ICU, mechanical ventilation, vasopressors, and RRT on day 28 was 5.6 ± 8.8 days, 5.3 ± 8.4 days, 10.1 ± 10.5 days and 9 ± 11.2 days, respectively.

3.5. Independent Mortality Risk Factors. For all the collected variables, we realized a bivariate analysis (Table 1), and then all the significant parameters were entered in a multivariate analysis. We found 6 independent variables associated with mortality: need for mechanical ventilation, SAPS II >60, chronic alcoholism, age >65 years, prothrombin ratio (PR) <40% and PaO$_2$/FiO$_2$ <150 (Table 2).

3.6. Comparison of the 2003–2004 and 2005–2007 Periods. The 2003–2004 period represented 41.9% of the population. The 2 groups were homogeneous for baseline characteristics except more chronic cardiac failures (27.8% versus 10.8%,...
Table 1: Mortality risk factors in septic shock patients: monovariate analysis. COPD: chronic obstructive pulmonary disease, SAPS: simplify acute physiology score, SOFA: sepsis-related organ failure assessment score, ICU: intensive care unit, RRT: renal replacement therapy, prothrombin ratio (PR).

| Comorbidities n(%) | Survivors 146 (45.6) | Deceased 174 (54.4) | P |
|--------------------|----------------------|---------------------|---|
| Chronic cardiac failure | 21(14.4) | 36(21) | .1233 |
| Diabete mellitus | 29(19.9) | 40(23.4) | .4479 |
| COPD | 35(23.9) | 45(26.3) | .6321 |
| Chronic liver failure | 11(7.5) | 24(14) | .0656 |
| Chronic alcoolism | 28(19.1) | 57(33.3) | .0046 |
| Chronic renal failure | 6(4.1) | 10(5.8) | .4810 |
| Non hematologic malignancy | 16(10.9) | 20(11.6) | .0108 |
| Hematologic malignancy | 16(10.9) | 16(9.3) | .6369 |
| Immunosuppression | 25(17.1) | 24(14) | .4484 |
| Clinical presentation | | | |
| Male sex n(%) | 92(63) | 111(63.8) | .8853 |
| Age (years) (mean ± SD) | 61.6 ± 15.5 | 68.5 ± 14.3 | <.0001 |
| Lactate (meq/l) (mean ± SD) | 3 ± 2.2 | 4.9 ± 4 | <.0001 |
| Platelet count (1000/mm³) (mean ± SD) | 203 ± 144 | 198 ± 143 | .7813 |
| Creatinine (mg/l) (mean ± SD) | 21.6 ± 15.4 | 22.7 ± 12.3 | .4825 |
| Bilirubine (mg/l) (mean ± SD) | 14.2 ± 13.5 | 20.6 ± 27.4 | .0157 |
| PR (%) (mean ± SD) | 58.6 ± 19.8 | 49.6 ± 20.5 | <.0001 |
| pH (mean ± SD) | 7.3 ± 0.1 | 7.2 ± 0.1 | .0007 |
| PaO2/FiO2 (mean ± SD) | 190 ± 103 | 154 ± 101 | .021 |
| SAPS II (mean ± SD) | 52.7 ± 13.9 | 70.3 ± 20.9 | <.0001 |
| SOFA score (mean ± SD) | 10.6 ± 3 | 11.9 ± 3.1 | .0002 |
| Respiratory failure n(%) | 123(84.2) | 153(88.4) | .2746 |
| Renal failure n(%) | 30(20.5) | 53(31.1) | .0323 |
| Coagulation failure n(%) | 21(14.3) | 29(17.2) | .4869 |
| Hepatic failure n(%) | 1(0.7) | 10(6) | .0108 |
| Neurologic failure n(%) | 40(28.5) | 70(41.6) | .0169 |
| Management | | | |
| Time from shock to ICU admission (hours) (mean ± SD) | 2.5 ± 5.6 | 2.2 ± 4 | .6034 |
| Adapted antibiotic therapy n(%) (mean ± SD) | 138(97.8) | 154(96.8) | .7269 |
| Time from sepsis to adapted antibiotic therapy (hours) (mean ± SD) | 8 ± 18.2 | 11.2 ± 19 | .1426 |
| Adequate antibiotic therapy n(%) | 89(92.7) | 76(83.5) | .0512 |
| Time from sepsis to adequate antibiotic therapy (hours) (mean ± SD) | 10.3 ± 23.3 | 15.4 ± 25.7 | .1698 |
| Mechanical ventilation n(%) | 116(79.4) | 166(95.9) | <.0001 |
| Noninvasive ventilation n(%) | 12(8.6) | 27(15.6) | .0614 |
| Time from shock to intubation (hours) (mean ± SD) | 2.5 ± 6.4 | 3.3 ± 9.8 | .4050 |
| RRT n(%) | 41(28) | 57(33.1) | .3304 |
| Time from shock to RRT (hours) (mean±SD) | 29 ± 38.7 | 29.7 ± 33.4 | .9216 |
| Crystalloid volume expansion at 6 hours of sepsis (mL) (mean ± SD) | 1302 ± 1123 | 974 ± 1127 | .0135 |
| Crystalloid volume expansion at 24 hours of sepsis (mL) (mean ± SD) | 2629 ± 1748 | 1842 ± 1618 | .0001 |
| Hydrocortisone n(%) | 123(84.2) | 147(84.4) | .9538 |
| Time from shock to initiation of hydrocortisone (hours) (mean ± SD) | 8.2 ± 13 | 7.4 ± 10.9 | .5985 |
| Activated proteine C n(%) | 13(8.9) | 8(4.6) | .1246 |
| Intensive insulin therapy n(%) | 94(64.3) | 86(49.4) | .0072 |
| Enteral nutrition n(%) | 101(70.6) | 67(51.1) | .0009 |
| Parenteral nutrition n(%) | 39(27.2) | 29(22.1) | .3256 |
| Time from shock to initiation of nutrition (days) (mean ± SD) | 2.5 ± 1.3 | 2.4 ± 1.1 | .7918 |
Table 2: Independent mortality risk factors in septic shock patients: multivariate analysis SAPS: simplify acute physiology score, prothrombin ratio (PR).

| Factor                        | Odds ratio | Confidence interval | P     |
|-------------------------------|------------|---------------------|-------|
| Mechanical ventilation        | 4.97       | [1.79–13.75]        | .0021 |
| SAPS II >60                   | 4.28       | [2.51–7.13]         | .0001 |
| Chronic alcoholism            | 3.38       | [1.75–6.52]         | .0003 |
| Age >65 years                 | 2.65       | [1.47–4.79]         | .0012 |
| PR <40%                       | 2.37       | [1.26–4.45]         | .0074 |
| PaO2/FiO2 <150                | 1.91       | [1.15–3.26]         | .00183|

\[ P = .001 \) and a lower SOFA score (10.9 ± 3.2 versus 11.6 ± 3.2, \( P = .0338 \)) during the 2003–2004 period. In contrast, the management of the 2 groups was very different: in the second period, norepinephrine became the vasoactive agent of choice (\( P < .0001 \)) instead of dopamine and dobutamine, initial plasma volume expansion was greater (\( P = .0005 \)), patients received more intensive insulin therapy (\( P < .0001 \)), and the delays of intubation (\( P = .01 \)), antibiotic therapy (\( P = .0037 \)), initiation of hydrocortisone (\( P = .0001 \)), RRT (\( P = .002 \)), and nutrition (\( P = .0389 \)) were shortened (Table 3).

Prognosis variables were also different between the 2 periods. We found during the period 2005–2007 an increase in the number of days alive free from mechanical ventilation (\( P = .0207 \)) and vasopressors (\( P = .0021 \)) on day 28, and a decrease in septic shock complications (\( P < .0001 \)). However, there was no difference in mortality (\( P = .79 \)). All the significant differences concerning the prognosis are presented Table 4.

4. Discussion

4.1. Epidemiology and Prognosis. Mean age was 65 years and there was a predominance of male. Three French epidemiologic studies found a similar repartition [1, 2, 7]. In contrast, our population was particularly severely ill; mean SAPS II and SOFA scores on admission were 62 and 11, respectively, compared to 58 and 9 in these studies [1, 2]. The infection was bacteriologically proven in 59% of the patients, as in the other studies [2, 8, 9]. Literature data also reveal a change in the origin of the sepsis with a decrease of intraabdominal and Gram-negative bacilli infections replaced by pulmonary and Gram-positive cocci infections [10–12]. It is in accordance with our results: half of the infections was coming from the respiratory tract and was caused by Gram-positive cocci. Annane, realizing a multicenter epidemiologic study between 1993 to 2000 found a 60.1% mortality rate, with an improvement from 1993 (62.1%) to 2000 (55.6%) [2]. This improvement seems to be related to an earlier and more aggressive management and an improvement in specific anti-infectious therapies [13–15]. ICU mortality in our study was 54.4%. Most other published studies found a 35% mortality rate, but patients with severe sepsis were also included [1, 10, 16–18].

We recovered six independent mortality risk factors: mechanical ventilation, SAPS II >60, chronic alcoholism, age >65 years, PR <40%, and PaO2/FiO2 ratio <150. These factors can easily be available on admission and allow screening immediately a group of patients with a high mortality risk. Our results confirm the classic risk factors associated with mortality recovered in the literature [1, 2, 7, 10]. Specifically regarding chronic alcoholism, numerous studies report its association with the frequency of infections [19, 20], but an important role in mortality in the absence of hepatic failure is not well known, except in the study by O’Brien [21] who found an increase in mortality in ICU patients suffering from chronic alcoholism, and particularly when patients developed severe sepsis and septic shock. Its deleterious effect was probably revealed by the high prevalence of alcoholism in our population (26.8%).

Most shocking is the absence of signification of antibiotic therapy. Numerous studies [9, 22, 23] showed an impairment of the prognosis when antibiotic therapy was delayed. In particular, Kumar found a 7.6% increased mortality for each hour delay of antibiotics [24]. Mean time for antibiotic therapy in our study was very long (9.77 hours), but it was calculated from the onset of the sepsis and not septic shock. Adequate antibiotic therapy improves the prognosis of patients suffering from septic shock. In our study, antibiotic therapy was adapted in 97% of the patients and adequate in 88%. These results are excellent, compared, for example, to a 2003 american study who found 23% of nonadapted antibiotic therapy, responsible of an increase in mortality [9]. These important percentages probably explain the absence of signification of antibiotics in our study.

4.2. Comparison of 2003–2004 and 2005–2007 Periods. In spite of a higher SOFA score during the 2005–2007 period, the mortality remained the same but some variables improved (diminution of septic shock complications, increase of the number of days alive free from mechanical ventilation and vasopressors on day 28). We tried to find if the evolution in the management of our patients could explain these differences. The first hours are critical in septic shock and the major difference in the management between the 2 periods was the rapidity to institute all medical or replacement therapies. Likewise, initial plasma volume expansion was greater in the last period. Nevertheless, these volumes of fluids (about 3.5 litres in 24 hours) are far below others studies where patients received nearly 5 or 6 litres [1, 3, 7, 11, 12, 14, 23]. The aggressive (‘early goal directed therapy’) [14] is recommended by
### Table 3: Baseline characteristics and management of septic shock patients: significant differences between the 2003-2004 and 2005–2007 periods. COPD: chronic obstructive pulmonary disease, SAPS: simplify acute physiology score, SOFA: sepsis-related organ failure assessment score, ICU: intensive care unit, RRT: renal replacement therapy, prothrombin ratio (PR).

| Comorbidities n(%) | 2003-2004 | 2005–2007 | P       |
|--------------------|-----------|-----------|---------|
| Chronic cardiac failure | 37(27.8)  | 20(10.8)  | .001    |
| Diabetic mellitus   | 34(25.6)  | 35(19)    | .16     |
| COPD                | 39(29.3)  | 41(22.3)  | .1544   |
| Chronic liver failure | 19(14.3)  | 16(8.7)   | .1171   |
| Chronic alcoholism  | (24.8)    | (28.3)    | .4939   |
| Chronic renal failure | 8(6)      | 8(4.3)    | .5034   |
| Non hematologic malignancy | 8(6)      | 28(15.2)  | .8367   |
| Hematologic malignancy | 18(13.5)  | 14(7.6)   | .084    |
| Immunossuppression  | 18(13.5)  | 31(16.8)  | .4205   |

| Clinical presentation | 2003-2004 | 2005–2007 | P        |
|-----------------------|-----------|-----------|----------|
| Male sex n(%)         | 82(61.2)  | 121(65)   | .4794    |
| Age (years) (mean ± SD) | 63.9 ± 15.2 | 66.5 ± 15.3 | .1374   |
| Lactate (meq/l) (mean ± SD) | 4.6 ± 4.1 | 3.7 ± 2.9 | .0993   |
| Platelet count (1000/mm³) (mean ± SD) | 180 ± 1410 | 215 ± 144 | .0345   |
| Creatinine (mg/l) (mean ± SD) | 22.4 ± 14.6 | 22.1 ± 13.3 | .8113   |
| Bilirubine (mg/l) (mean ± SD) | 20.8 ± 21.1 | 15.4 ± 22.4 | .0425   |
| PR (%) (mean ± SD)    | 52.1 ± 21.5 | 55.1 ± 20.1 | .2117   |
| pH (mean ± SD)        | 7.29 ± 0.14 | 7.29 ± 0.13 | .7409   |
| PaO2/FiO2 (mean ± SD) | 161.1 ± 96.4 | 177.9 ± 107.9 | .1649   |
| SAPS II (mean ± SD)   | 60.8 ± 20.1 | 63.4 ± 20.1 | .259    |
| SOFA score (mean ± SD) | 10.9 ± 3.2 | 11.6 ± 3.2 | .0338   |

| Management | 2003-2004 | 2005–2007 | P        |
|------------|-----------|-----------|----------|
| Mechanical ventilation n(%) | (85.1)    | (90.8)    | .1143    |
| Norepinephrine n(%) | 79(59)    | 158(85.4) | <.0001   |
| Dobutamine n(%)    | 51(38.1)  | 32(17.4)  | <.0001   |
| Dopamine n(%)      | 91(67.9)  | 43(23.4)  | <.001    |
| Intensive insulin therapy n(%) | 17(12.7) | 163(87.6) | <.0001   |
| Time from sepsis to adapted antibiotic treatment (hours) (mean ± SD) | 13.9 ± 18.7 | 7.2 ± 18.3 | .0037   |
| Cristalloid volume expansion at 6 hours of sepsis (mean ± SD) | 816 ± 1038 | 1323 ± 1155 | .0001   |
| Cristalloid volume expansion at 24 hours of sepsis (mean ± SD) | 1773 ± 1674 | 2479 ± 1696 | .0005   |
| Time from shock to intubation (hours) (mean ± SD) | 11.3 ± 14 | 5.6 ± 9.8 | .0001   |
| Time from shock to intubation (hours) (mean ± SD) | 4.6 ± 11.9 | 1.9 ± 5.2 | .0105   |
| Time from shock to RRT (hours) (mean ± SD) | 43.6 ± 42 | 20.8 ± 28.1 | .002    |
| Time from shock to initiation of nutrition (days) (mean ± SD) | 2.7 ± 1.4 | 2.3 ± 1.1 | .0389   |

### Table 4: Prognosis of septic shock patients: comparison between the 2003-2004 and 2005–2007 periods. ICU: intensive care unit, RRT: renal replacement therapy.

| Septic shock complications n(%) | 2003-2004 | 2005–2007 | P        |
|--------------------------------|-----------|-----------|----------|
| Number of days alive free from mechanical ventilation on day 28 (mean ± SD) | 3.9 ± 6.9 | 6.2 ± 9.1 | .0207   |
| Number of days alive free from vaspressors on day 28 (mean ± SD) | 8 ± 9.6 | 11.6 ± 10.9 | .0021   |
| Number of days alive free from RRT on day 28 (mean ± SD) | 8.6 ± 12.1 | 9.2 ± 10.7 | .76     |
| Patients discharged from ICU on day 28 n(%) | 46(34.6) | 69(37.1) | .6452    |
| ICU death n(%) | 74(55.2) | 100(53.8) | .7958    |
the SSC [3], because of its beneficial effect on mortality. Even with an increase in plasma volume expansion between the 2 periods, it remains probably too low. This is well explained by the difficulty to translate prospective controlled studies in daily clinical practice. Moreover, we collected the data from the onset of the sepsis when patients were often hospitalized in other units and physicians who are not intensivists are not sensitized to the importance of an aggressive volume expansion.

Regarding the hemodynamic support, norepinephrine became the vasopressor of choice in replacement of dopamine. Likewise, the dobutamine was used very often before 2005 and its indication was restricted after. This is conforming to the recommendations of the SSC [3]. Activated protein C is a controversial treatment of septic shock and is not a high grade recommendation in the 2008 SSC [25]. Waiting for the results of ongoing studies, we do not often use this molecule (4.5% and 8.1% of the patients during the 2 periods), so we cannot evaluate it in our study. Hydrocortisone was largely used during the 2 periods (80.6% and 87.1%), following the study published by Annane in 2002 [26]. Finally, the 2004 recommendations [3] have contributed to introduce more intensive insulin therapy in our ICU. Van den Berghe et al. [27] have demonstrated in 2001 a reduction of mortality in surgical patients when maintaining glycaemia between 0.8 to 1.1 g/l with a decrease in multiorgan failures secondary to septic shock. The same team [28] did not confirm their results in a population of medical patients and the study recently published by Arabi do not support this intensive strategy [29]. In our study, we did not find deleterious effect of insulin, but we did not recorded hypoglycaemia.

5. Conclusion

The six mortality risk factors recovered in the multivariate analysis can easily be available on admission and allow screening immediately a group of patients with a high mortality risk. Concerning the evolution of the management during these 5 years, even if it is difficult in usual practice to be completely in accordance with recommendations, we remark an earlier introduction of numerous replacement and medical therapies as well as a more initial aggressive volume expansion. This probably explains the improvement in morbidity, whereas mortality did not change.

References

[1] C. Brun-Buisson, P. Meshaka, P. Pinton, and B. Vallet, “EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units,” Intensive Care Medicine, vol. 30, no. 4, pp. 580–588, 2004.
[2] D. Annane, P. Aegerter, M. C. Jars-Guinestre, and B. Guidet, “Current epidemiology of septic shock: the CUB-Réa network,” American Journal of Respiratory and Critical Care Medicine, vol. 168, no. 2, pp. 165–172, 2003.
[3] R. P. Dellinger, J. M. Carlet, H. Masur et al., “Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock,” Critical Care Medicine, vol. 32, no. 3, pp. 858–873, 2004.
[4] J.-R. Le Gall, S. Lemeshow, and F. Saulnier, “A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study,” Journal of the American Medical Association, vol. 270, no. 24, pp. 2957–2963, 1993.
[5] J.-L. Vincent, R. Moreno, J. Takala et al., “The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure,” Intensive Care Medicine, vol. 22, no. 7, pp. 707–710, 1996.
[6] R. C. Bone, R. A. Balk, F. B. Cerra et al., “Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis,” Chest, vol. 101, no. 6, pp. 1644–1655, 1992.
[7] C. Brun-Buisson, F. Doyon, J. Carlet et al., “Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: a multicenter prospective study in intensive care units,” Journal of the American Medical Association, vol. 274, no. 12, pp. 968–974, 1995.
[8] P. D. Annane, P. E. Bellissant, and J.-M. Cavaillon, “Septic shock,” Lancet, vol. 365, no. 9453, pp. 63–78, 2000.
[9] S. Harbarth, J. Garbino, J. Pugin, J. A. Romand, D. Lew, and D. Pittet, “Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis,” American Journal of Medicine, vol. 115, no. 7, pp. 529–535, 2003.
[10] D. C. Angus, W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky, “Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care,” Critical Care Medicine, vol. 29, no. 7, pp. 1303–1310, 2001.
[11] J. A. Russell, “The current management of septic shock,” Minerva Medica, vol. 99, no. 5, pp. 431–458, 2008.
[12] G. Friedman, E. Silva, J.-L. Vincent et al., “Has the mortality of septic shock changed with time?” Critical Care Medicine, vol. 26, no. 12, pp. 2078–2086, 1998.
[13] V. Nobre, F. P. Sarasin, and J. Pugin, “Prompt antibiotic administration and goal-directed hemodynamic support in patients with severe sepsis and septic shock,” Current Opinion in Critical Care, vol. 13, no. 5, pp. 586–591, 2007.
[14] E. Rivers, B. Nguyen, S. Havstad et al., “Early goal-directed therapy in the treatment of severe sepsis and septic shock,” The New England Journal of Medicine, vol. 345, no. 19, pp. 1368–1377, 2001.
[15] R. Iscimen, R. Cartin-Ceba, M. Yilmaz et al., “Risk factors for the development of acute lung injury in patients with septic shock: an observational cohort study,” Critical Care Medicine, vol. 36, no. 5, pp. 1518–1522, 2008.
[16] C. Alberti, C. Brun-Buisson, H. Burchardi et al., “Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study,” Intensive Care Medicine, vol. 28, no. 2, pp. 108–121, 2002.
[17] J.-L. Vincent, Y. Sakr, C. L. Sprung et al., “Sepsis in European intensive care units: results of the SOAP study,” Critical Care Medicine, vol. 34, no. 2, pp. 344–353, 2006.
[18] J. Blanco, A. Muriel-Bombín, V. Sagredo et al., “Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study,” Critical Care, vol. 12, no. 6, 2008.
[19] L. E. Diaz, A. Montero, M. Gonzalez-Gross, A. I. Vallejo, J. Romeo, and A. Marcos, “Influence of alcohol consumption on immunological status: a review,” European Journal of Clinical Nutrition, vol. 56, no. 3, pp. S50–S53, 2002.
[20] V. von Dossow, C. Schilling, S. Beller et al., “Altered immune parameters in chronic alcoholic patients at the onset of infection and of septic shock,” Critical Care, vol. 8, no. 5, pp. R312–321, 2004.

[21] J. M. O’Brien Jr., B. Lu, N. A. Ali et al., “Alcohol dependence is independently associated with sepsis, septic shock, and hospital mortality among adult intensive care unit patients,” Critical Care Medicine, vol. 35, no. 2, pp. 345–350, 2007.

[22] H. Gerlach and D. Keh, “Recent progress in sepsis epidemiology—have we learned enough?” Critical Care, vol. 7, no. 5, pp. 333–334, 2003.

[23] P.-Y. Bochud, M. Bonten, O. Marchetti, and T. Calandra, “Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review,” Critical Care Medicine, vol. 32, no. 11, pp. S495–S512, 2004.

[24] A. Kumar, D. Roberts, K. E. Wood et al., “Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock,” Critical Care Medicine, vol. 34, no. 6, pp. 1589–1596, 2006.

[25] R. P. Dellinger, M. M. Levy, J. M. Carlet et al., “Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008,” Intensive Care Medicine, vol. 34, no. 1, pp. 17–60, 2008.

[26] D. Annane, V. Sèbille, C. Charpentier et al., “Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock,” Journal of the American Medical Association, vol. 288, no. 7, pp. 862–871, 2002.

[27] G. Van Den Berghe, P. Wouters, F. Weekers et al., “Intensive insulin therapy in critically ill patients,” The New England Journal of Medicine, vol. 345, no. 19, pp. 1359–1367, 2001.

[28] G. van den Berghe, A. Wilmer, G. Hermans et al., “Intensive insulin therapy in the medical ICU,” The New England Journal of Medicine, vol. 354, no. 5, pp. 449–461, 2006.

[29] Y. M. Arabi, O. C. Dabbagh, H. M. Tamim et al., “Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients,” Critical Care Medicine, vol. 36, no. 12, pp. 3190–3197, 2008.